As antibiotic-resistant bacteria become more urgent threats worldwide, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced today up to $102.5 million in renewed funding over seven years for the Antibacterial Resistance Leadership Group (ARLG). This funding will allow the network to continue and enhance its mission to prioritize, design, and execute clinical research to reduce the public health threat of antibacterial resistance.
Composed of more than 50 leading experts working together to innovate clinical trial design, inform guidelines, and improve clinical practice in infectious diseases, the ARLG received its initial funding in 2013.
Vance Fowler, M.D., of Duke University and Henry Chambers, M.D., of the University of California, San Francisco, will continue to serve as the ARLG principal investigators. The ARLG will include several centers that will support essential network functions:
- The Scientific Leadership Center will provide administrative guidance and oversight, prioritize the research agenda and ensure timely publication of results.
- The Clinical Operations Center will provide clinical support for studies and trials, select sites, oversee protocol teams and ensure that the trials are aligned with ARLG priorities.
- The Laboratory Center will oversee laboratory research and ensure that the specimens from clinical trials are processed, analyzed, and stored appropriately.
- The Statistics and Data Management Center will assist with study design and analysis to ensure high-quality data.
With clinical operations based at the Duke Clinical Research Institute, the ARLG’s research team has collaborations in 19 countries and has initiated more than 40 clinical research studies involving more than 20,000 patients across more than 130 sites. Its three areas of research align with the Centers for Disease Control and Prevention antibiotic resistance threats and include:
- Infections caused by Gram-negative bacteria, such as Escherichia coli;
- Infections caused by Gram-positive bacteria, such as Staphylococcus aureus; and
- Diagnostics such as rapid point-of-care tests to detect drug resistance, guide antibacterial therapy, and support clinical trials.
“The renewal support from the NIAID will allow the ARLG to continue its collaborative work to advance science in antibacterial research, and to provide funding opportunities for the next generation of researchers dedicated to addressing this public health threat,” said Vance Fowler, M.D., ARLG co-principal investigator, member of the DCRI, and professor of medicine at the Duke University School of Medicine.
“We are delighted to be able to continue to support efforts to fight antibiotic resistance by generating data that is used to inform dosing guidelines and developing diagnostic testing for better detection and timely treatment,” Fowler said.
The ARLG is funded through grant UM1AI104681.